Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Highly Diastereoselective Synthesis of a HCV NS5B Nucleoside Polymerase Inhibitor.

Zhong YL, Cleator E, Liu Z, Yin J, Morris WJ, Alam M, Bishop B, Dumas AM, Edwards J, Goodyear A, Mullens P, Song ZJ, Shevlin M, Thaisrivongs DA, Li H, Sherer EC, Cohen RD, Yin J, Tan L, Yasuda N, Limanto J, Davies A, Campos KR.

J Org Chem. 2019 Apr 19;84(8):4780-4795. doi: 10.1021/acs.joc.8b02500. Epub 2018 Dec 10.

PMID:
30475616
3.

A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).

Thaisrivongs DA, Morris WJ, Tan L, Song ZJ, Lyons TW, Waldman JH, Naber JR, Chen W, Chen L, Zhang B, Yang J.

Org Lett. 2018 Mar 16;20(6):1568-1571. doi: 10.1021/acs.orglett.8b00259. Epub 2018 Feb 26.

PMID:
29481097
4.

Palladium-Catalyzed Enantioselective Synthesis of Cyclic Sulfamidates and Application to a Synthesis of Verubecestat.

Chen W, Meng D, N'Zemba B, Morris WJ.

Org Lett. 2018 Mar 2;20(5):1265-1268. doi: 10.1021/acs.orglett.7b03639. Epub 2018 Feb 20.

PMID:
29461065
5.

Macrocyclic glycopeptide chiral selectors bonded to core-shell particles enables enantiopurity analysis of the entire verubecestat synthetic route.

Barhate CL, Lopez DA, Makarov AA, Bu X, Morris WJ, Lekhal A, Hartman R, Armstrong DW, Regalado EL.

J Chromatogr A. 2018 Mar 2;1539:87-92. doi: 10.1016/j.chroma.2018.01.042. Epub 2018 Jan 31.

PMID:
29397980
6.

High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.

Pickles T, Morris WJ, Keyes M.

Brachytherapy. 2017 Nov - Dec;16(6):1101-1105. doi: 10.1016/j.brachy.2017.08.003. Epub 2017 Oct 12.

PMID:
29032014
7.

Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.

Pickles T, Tyldesley S, Hamm J, Virani SA, Morris WJ, Keyes M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):45-52. doi: 10.1016/j.ijrobp.2017.08.042. Epub 2017 Sep 4.

PMID:
29029889
8.

In Regard to Ciezki et al.

Morris WJ, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):240-242. doi: 10.1016/j.ijrobp.2017.04.035. Epub 2017 Aug 7. No abstract available.

PMID:
28816154
9.

Focal application of low-dose-rate brachytherapy for prostate cancer: a pilot study.

Mahdavi SS, Spadinger IT, Salcudean SE, Kozlowski P, Chang SD, Ng T, Lobo J, Nir G, Moradi H, Peacock M, Morris WJ.

J Contemp Brachytherapy. 2017 Jun;9(3):197-208. doi: 10.5114/jcb.2017.68424. Epub 2017 Jun 13.

10.

The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.

Dosani M, Morris WJ, Tyldesley S, Pickles T.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):696-701. doi: 10.1016/j.clon.2017.06.009. Epub 2017 Jul 13.

PMID:
28712786
11.

ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Rodda S, Morris WJ, Hamm J, Duncan G.

Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):581-589. doi: 10.1016/j.ijrobp.2017.02.027. Epub 2017 Feb 21.

PMID:
28581398
12.

In Reply to Hamstra et al.

Morris WJ.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):482. doi: 10.1016/j.ijrobp.2017.01.024. No abstract available.

PMID:
28463169
13.

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6.

PMID:
28433432
14.

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24.

PMID:
28262473
15.

Synthesis of the γ-Secretase Modulator MK-8428.

Miller SP, Morris WJ, Orr RK, Eckert J, Milan J, Maust M, Cowden C, Cui J.

J Org Chem. 2017 Mar 17;82(6):2957-2964. doi: 10.1021/acs.joc.6b02979. Epub 2017 Mar 6.

PMID:
28262021
16.

Robustness to source displacement in dual air kerma strength planning for focal low-dose-rate brachytherapy of prostate cancer.

Mahdavi SS, Spadinger IT, Chng NT, Morris WJ.

Brachytherapy. 2016 Sep-Oct;15(5):642-9. doi: 10.1016/j.brachy.2016.04.388. Epub 2016 Jun 1.

PMID:
27263060
17.

Rectal Ulcers and Rectoprostatic Fistulas after (125)I Low Dose Rate Prostate Brachytherapy.

Leong N, Pai HH, Morris WJ, Keyes M, Pickles T, Tyldesley S, Wu J; British Columbia Cancer Agency.

J Urol. 2016 Jun;195(6):1811-6. doi: 10.1016/j.juro.2015.12.095. Epub 2016 Jan 14.

PMID:
26778712
18.

Learning-Based Multi-Label Segmentation of Transrectal Ultrasound Images for Prostate Brachytherapy.

Nouranian S, Ramezani M, Spadinger I, Morris WJ, Salcudean SE, Abolmaesumi P.

IEEE Trans Med Imaging. 2016 Mar;35(3):921-32. doi: 10.1109/TMI.2015.2502540. Epub 2015 Nov 20.

PMID:
26599701
19.

Statistical Biomechanical Surface Registration: Application to MR-TRUS Fusion for Prostate Interventions.

Khallaghi S, Sánchez CA, Rasoulian A, Nouranian S, Romagnoli C, Abdi H, Chang SD, Black PC, Goldenberg L, Morris WJ, Spadinger I, Fenster A, Ward A, Fels S, Abolmaesumi P.

IEEE Trans Med Imaging. 2015 Dec;34(12):2535-49. doi: 10.1109/TMI.2015.2443978. Epub 2015 Jun 11.

PMID:
26080380
20.

Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.

Lo AC, Morris WJ, Pickles T, Keyes M, McKenzie M, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):745-51. doi: 10.1016/j.ijrobp.2014.12.014.

PMID:
25752387
21.

Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity.

Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ.

Brachytherapy. 2015 May-Jun;14(3):342-9. doi: 10.1016/j.brachy.2015.01.002. Epub 2015 Feb 26.

PMID:
25727178
22.

Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy.

Spadinger I, Chu J, Afsari Golshan M, Keyes M, Pickles T, Hamm J, Morris WJ.

Brachytherapy. 2015 May-Jun;14(3):350-8. doi: 10.1016/j.brachy.2014.12.004. Epub 2015 Jan 29.

PMID:
25638507
23.

A multi-atlas-based segmentation framework for prostate brachytherapy.

Nouranian S, Mahdavi SS, Spadinger I, Morris WJ, Salcudean SE, Abolmaesumi P.

IEEE Trans Med Imaging. 2015 Apr;34(4):950-61. doi: 10.1109/TMI.2014.2371823. Epub 2014 Dec 2.

PMID:
25474806
24.

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

Hamilton SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T, Lapointe V, Kahnamelli A, McKenzie M, Miller S, Morris WJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):934-41. doi: 10.1016/j.ijrobp.2014.07.032. Epub 2014 Sep 17.

PMID:
25240272
25.

Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience.

Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ, Tyldesley S.

Urol Oncol. 2015 Feb;33(2):66.e13-9. doi: 10.1016/j.urolonc.2014.07.009. Epub 2014 Aug 29.

PMID:
25168459
26.

Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.

Keyes M, Miller S, Pickles T, Halperin R, Kwan W, Lapointe V, McKenzie M, Spadinger I, Pai H, Chan EK, Morris WJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):570-8. doi: 10.1016/j.ijrobp.2014.06.037. Epub 2014 Aug 20.

PMID:
25151536
27.

An automatic multi-atlas segmentation of the prostate in transrectal ultrasound images using pairwise atlas shape similarity.

Nouranian S, Mahdavi SS, Spadinger I, Morris WJ, Salcudean SE, Abolmaesumi P.

Med Image Comput Comput Assist Interv. 2013;16(Pt 2):173-80.

PMID:
24579138
28.

Intraoperative segmentation of iodine and palladium radioactive sources in C-arm images.

Amat di San Filippo C, Fichtinger G, Morris WJ, Salcudean SE, Dehghan E, Fallavollita P.

Int J Comput Assist Radiol Surg. 2014 Sep;9(5):769-76. doi: 10.1007/s11548-014-0983-2. Epub 2014 Feb 7.

PMID:
24504857
29.

Rebuttal to Drs Stone and Stock.

Spadinger I, Morris WJ.

Brachytherapy. 2014 Jan-Feb;13(1):44-5. doi: 10.1016/j.brachy.2013.11.010. Epub 2013 Dec 18. No abstract available.

PMID:
24361247
30.

Treatment options for localized prostate cancer.

Keyes M, Crook J, Morton G, Vigneault E, Usmani N, Morris WJ.

Can Fam Physician. 2013 Dec;59(12):1269-74. Review.

31.

Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.

Lo AC, Morris WJ, Lapointe V, Hamm J, Keyes M, Pickles T, McKenzie M, Spadinger I.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93. doi: 10.1016/j.ijrobp.2013.10.010.

PMID:
24331654
32.

Decline in acute urinary toxicity: a long-term study in 2011 patients with prostate brachytherapy within a provincial institution.

Chan EK, Keyes M, Pickles T, Lapointe V, Spadinger I, McKenzie M, Morris WJ.

Brachytherapy. 2014 Jan-Feb;13(1):46-52. doi: 10.1016/j.brachy.2013.10.005. Epub 2013 Nov 7.

PMID:
24210697
33.

Whole prostate D90 and V100: a dose-response analysis of 2000 consecutive (125)I monotherapy patients.

Morris WJ, Spadinger I, Keyes M, Hamm J, McKenzie M, Pickles T.

Brachytherapy. 2014 Jan-Feb;13(1):32-41. doi: 10.1016/j.brachy.2013.08.006. Epub 2013 Oct 11.

PMID:
24126102
34.

Pride or prejudice: does Phoenix flatter radiation therapy?

Morris WJ, Pickles T, Keyes M, McKenzie M, Spadinger I.

Brachytherapy. 2014 May-Jun;13(3):299-303. doi: 10.1016/j.brachy.2013.06.006. Epub 2013 Aug 14.

PMID:
23953812
35.

DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.

Keyes M, Macaulay C, Hayes M, Korbelik J, Morris WJ, Palcic B.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):829-34. doi: 10.1016/j.ijrobp.2013.04.011. Epub 2013 May 18.

PMID:
23688814
36.

Canadian prostate brachytherapy in 2012.

Keyes M, Crook J, Morris WJ, Morton G, Pickles T, Usmani N, Vigneault E.

Can Urol Assoc J. 2013 Jan-Feb;7(1-2):51-8. doi: 10.5489/cuaj.218.

37.

Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer.

Morris WJ, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, Pai H, Pickles T, Tyldesley S.

Cancer. 2013 Apr 15;119(8):1537-46. doi: 10.1002/cncr.27911. Epub 2012 Dec 26.

38.

Stereoselective addition of 2-phenyloxazol-4-yl trifluoromethanesulfonate to N-sulfinyl imines: application to the synthesis of the HCV protease inhibitor boceprevir.

Morris WJ, Muppalla KK, Cowden C, Ball RG.

J Org Chem. 2013 Jan 18;78(2):706-10. doi: 10.1021/jo301856f. Epub 2012 Dec 20.

PMID:
23215022
39.

Prostate brachytherapy training with simulated ultrasound and fluoroscopy images.

Goksel O, Sapchuk K, Morris WJ, Salcudean SE.

IEEE Trans Biomed Eng. 2013 Apr;60(4):1002-12. doi: 10.1109/TBME.2012.2222642. Epub 2012 Oct 3.

PMID:
23047861
40.

Fusion of ultrasound B-mode and vibro-elastography images for automatic 3D segmentation of the prostate.

Mahdavi SS, Moradi M, Morris WJ, Goldenberg SL, Salcudean SE.

IEEE Trans Med Imaging. 2012 Nov;31(11):2073-82. doi: 10.1109/TMI.2012.2209204. Epub 2012 Jul 17.

PMID:
22829391
41.

Seed localization in ultrasound and registration to C-arm fluoroscopy using matched needle tracks for prostate brachytherapy.

Moradi M, Mahdavi SS, Dehghan E, Lobo JR, Deshmukh S, Morris WJ, Fichtinger G, Salcudean ST.

IEEE Trans Biomed Eng. 2012 Sep;59(9):2558-67. doi: 10.1109/TBME.2012.2206808. Epub 2012 Jun 29.

PMID:
22759435
42.

Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease.

Pai HH, Keyes M, Morris WJ, Christie J.

Brachytherapy. 2013 Mar-Apr;12(2):126-33. doi: 10.1016/j.brachy.2012.04.008. Epub 2012 Jun 26.

PMID:
22738665
43.

Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program.

Keyes M, Morris WJ, Spadinger I, Araujo C, Cheung A, Chng N, Crook J, Halperin R, Lapointe V, Miller S, Pai H, Pickles T.

Brachytherapy. 2013 Jul-Aug;12(4):343-55. doi: 10.1016/j.brachy.2012.03.006. Epub 2012 Jun 21.

PMID:
22727470
44.

Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?

Pickles T, Hamm J, Morris WJ, Schreiber WE, Tyldesley S.

BJU Int. 2012 Dec;110(11 Pt B):E500-7. doi: 10.1111/j.1464-410X.2012.11190.x. Epub 2012 May 7.

45.

Segmentation of iodine brachytherapy implants in fluoroscopy.

Moult E, Fichtinger G, Morris WJ, Salcudean SE, Dehghan E, Fallavollita P.

Int J Comput Assist Radiol Surg. 2012 Nov;7(6):871-9. doi: 10.1007/s11548-012-0679-4. Epub 2012 Mar 25.

PMID:
22447486
46.

Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study.

Herbert C, Morris WJ, Keyes M, Hamm J, Lapointe V, McKenzie M, Pickles T, Spadinger I.

Radiother Oncol. 2012 May;103(2):228-32. doi: 10.1016/j.radonc.2012.01.006. Epub 2012 Feb 10.

PMID:
22326573
47.

Prostate brachytherapy postimplant dosimetry: seed orientation and the impact of dosimetric anisotropy in stranded implants.

Chng N, Spadinger I, Rasoda R, Morris WJ, Salcudean S.

Med Phys. 2012 Feb;39(2):721-31. doi: 10.1118/1.3671921.

PMID:
22320782
48.

Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.

Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH.

Cancer. 2012 Sep 1;118(17):4156-65. doi: 10.1002/cncr.26687. Epub 2012 Jan 17.

49.

Use of needle track detection to quantify the displacement of stranded seeds following prostate brachytherapy.

Lobo JR, Moradi M, Chng N, Dehghan E, Morris WJ, Fichtinger G, Salcudean SE.

IEEE Trans Med Imaging. 2012 Mar;31(3):738-48. doi: 10.1109/TMI.2011.2178254. Epub 2011 Dec 6.

PMID:
22156980
50.

Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%.

Herbert C, Liu M, Tyldesley S, Morris WJ, Joffres M, Khaira M, Kwan W, Moiseenko V, Pickles T.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):22-7. doi: 10.1016/j.ijrobp.2011.05.076. Epub 2011 Nov 11.

PMID:
22079724

Supplemental Content

Loading ...
Support Center